Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously reported on March 18, 2022, Scopus BioPharma Inc. (the "Company") received deficiency notification letters from the Listing Qualifications Staff of the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq's majority independent director requirement (the "Majority Independent Requirement") and audit and compensation committee requirements ("Audit and Compensation Committee Requirements"), each as set forth in Nasdaq Listing Rule 5605.

With the previously reported appointment of Raphael Hofstein, Ph.D. to the Board of Directors (the "Board") on April 29, 2022 and the resignation of Ashish Sanghrajka from the Board on May 4, 2022, the Company had regained compliance with the Majority Independent Requirement and Audit and Compensation Committee Requirements, which was confirmed by Nasdaq on May 16, 2022. With the subsequent resignation of Paul Hopper on May 18, 2022, as previously reported, the Company is no longer in compliance with the Majority Independent Requirement as of such date, but remains in compliance with the Audit and Compensation Committee Requirements. Accordingly, on May 23, 2022, the Company received a deficiencynotification letter from Nasdaq indicating that the Company is not in compliance with Nasdaq's Majority Independent Requirement.

Consistent with Nasdaq Listing Rules 5605(b)(1)(A), Nasdaq has provided the Company a new cure period in order to regain compliance with the Majority Independent Requirement: (i) until the earlier of the Company's next annual stockholders' meeting or May 18, 2023, or (ii) if the next annual stockholders' meeting is held before November 14, 2022, then the Company must evidence compliance no later than November 14, 2022.

This Current Report on Form 8-K is filed to satisfy the obligation under Nasdaq Listing Rule 5810(b) and Item 3.01(a) of Form 8-K that the Company publicly disclose the deficiency within four (4) business days after the date of the deficiency letter.

© Edgar Online, source Glimpses